Viatris
Pays vs peer median
×0.70
-30% premium
Sample
3
low confidence
Last refreshed
2026-04-13
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | Sotagliflozin (Inpefa) | Lexicon Pharmaceuticals | HF (HFrEF and HFpEF) | approved | $185M | $500M |
| 2024 | thrombosis | Idorsia | thrombosis | phase_3 | $350M | $350M |
| 2023 | myopiaProgression | Ocuphire Pharma | myopiaProgression | phase_3 | $30M | $400M |
| 2022 | Tyrvaya (varenicline nasal spray) | Oyster Point Pharma | Dry Eye Disease | approved | $750M | $750M |
How this is computed
For each Viatris deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.501, clamped to [0.7, 1.5].